Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia.

Cassileth PA, Begg CB, Bennett JM, Bozdech M, Kahn SB, Weiler C, Glick JH.

Blood. 1984 Apr;63(4):843-7.

2.
3.

A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.

Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Bickers JN, Hynes HE, Welborn JL, Simon SR, Grever M.

Blood. 1996 Oct 15;88(8):2841-51.

4.

A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.

Vogler WR, Winton EF, Gordon DS, Raney MR, Go B, Meyer L.

Blood. 1984 May;63(5):1039-45.

5.

A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.

Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R; Japan Adult Leukemia Study Group AML 97 Study.

Cancer. 2005 Dec 15;104(12):2726-34.

7.

A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.

Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, Cobcroft R, Herrmann R, Van Der Weyden M, Lowenthal RM, Page F, Garson OM, Juneja S.

Blood. 1996 Mar 1;87(5):1710-7.

8.

6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.

Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A; German AML Cooperative Group.

J Clin Oncol. 2003 Dec 15;21(24):4496-504.

PMID:
14673036
9.

Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.

Büchner T, Urbanitz D, Hiddemann W, Rühl H, Ludwig WD, Fischer J, Aul HC, Vaupel HA, Kuse R, Zeile G, et al.

J Clin Oncol. 1985 Dec;3(12):1583-9.

PMID:
3906048
10.

Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results.

Linkesch W, Michlmayr G, Gerhartz H, Illinger H, König H, Düllmann J, Keilhauer R, Moldrzyk D.

Onkologie. 1989 Feb;12(1):8-10.

PMID:
2654791
11.

Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial.

Stein RS, Vogler WR, Winton EF, Cohen HJ, Raney MR, Bartolucci A.

Leuk Res. 1990;14(10):895-903.

PMID:
2259226
12.
13.

Chemotherapy for adult acute nonlymphocytic leukemia with daunorubicin and cytosine arabinoside.

Cassileth PA, Katz ME.

Cancer Treat Rep. 1977 Nov;61(8):1441-5.

PMID:
922749
16.

A randomized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GIMEMA.

Mandelli F, Vegna ML, Avvisati G, Amadori S, Spadea A, Cacciola E, Cantore N, De Laurenzi A, De Rosa C, Fioritoni G, et al.

Ann Hematol. 1992 Apr;64(4):166-72.

PMID:
1581404
17.

Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.

Kobayashi T, Miyawaki S, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, Minami S, Minato K, Tsubaki K, Ohmoto E, Oh H, Jinnai I, Sakamaki H, Hiraoka A, Kanamaru A, Takahashi I, Saito K, Naoe T, Yamada O, Asou N, Kageyama S, Emi N, Matsuoka A, Tomonaga M, Ohno R, et al.

J Clin Oncol. 1996 Jan;14(1):204-13.

PMID:
8558199
18.

The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia.

Woods WG, Ruymann FB, Lampkin BC, Buckley JD, Bernstein ID, Srivastava AK, Smithson WA, Benjamin DR, Feig SA, Kim TH, et al.

Cancer. 1990 Sep 15;66(6):1106-13.

19.

High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update.

Wolff SN, Herzig RH, Phillips GL, Lazarus HM, Greer JP, Stein RS, Ray WA, Herzig GP.

Semin Oncol. 1987 Jun;14(2 Suppl 1):12-7.

PMID:
3589687
20.
Items per page

Supplemental Content

Write to the Help Desk